SCHEMBL562245

SCHEMBL562245

[CH2]c1cc(-c2ccc(F)cc2)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.47
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
CXCR1 P25024 1/20 0.43
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
GALR3 O60755 1/20 0.41
STAT3 P40763 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
ASIC1 P78348 1/20 0.40
MAOB P27338 1/20 0.39
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17502568 0.82 CYP3A4 (0.56) LMNAMEN1ALDH1A1KMT2ACYP3A4
SCHEMBL2301989 0.80 RAB9A (0.56) RAB9ANPC1CXCR1MAPTSMN1; SMN2
SCHEMBL3751941 0.79 RAB9A (0.61) PTGS2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL9220990 0.76 PTGS2 (0.47) PTGS2RAB9ANPC1CXCR1MAPT
SCHEMBL2159980 0.76 PTGS2 (0.51) PTGS2RAB9ANPC1CXCR1MAPT
SCHEMBL562246 0.76 RAB9A (0.53) PTGS2RAB9ANPC1CXCR1MAPT
SCHEMBL6352556 0.76 NPC1 (0.59) PTGS2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL28440906 0.73 MAPT (0.52) PTGS2RAB9ANPC1CXCR1MAPT
SCHEMBL2319256 0.73 LMNA (0.52) PTGS2RAB9ANPC1CXCR1MAPT
SCHEMBL103310 0.72 NOTUM (0.70) PTGS2RAB9ANPC1CXCR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US claimed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP claimed
WO-2007143526-A2 SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-12-13 WO claimed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO claimed
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007143526-A2 SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-12-13 WO disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 PTGS2 207/4885RAB9A 3540/4885NPC1 3917/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 PTGS2 189/4885RAB9A 3526/4885NPC1 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.